Pharmaceutical

AbbVie’s migraine medication Qulipta gets positive CHMP opinion

The medication could be a strong contender in the EU migraine market as a daily CGRP antagonist for migraines.

Jun 23, 2023 - 20:00
AbbVie’s migraine medication Qulipta gets positive CHMP opinion
The medication could be a strong contender in the EU migraine market as a daily CGRP antagonist for migraines.
Read the original article

Tags:

Previous Article

STAT+: European companies outline opposition to proposed overhaul of pharma policy

Next Article

Intercept winds down NASH programme after FDA pulls plug on Ocaliva

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Candel wins FDA orphan drug designation for pancreatic cancer drug

Candel wins FDA orphan drug designation for pancreatic ...

Apr 13, 2024

STAT+: FDA advisers vote against approving Intercept’s NASH drug

STAT+: FDA advisers vote against approving Intercept’s ...

May 19, 2023

BGBA-3055 by BeiGene for Solid Tumor: Likelihood of App...

Oct 3, 2023